Abstract
The BCR/ABL oncogene is the product of the Philadelphia (Ph) chromosome, the derivative (22q) product of a balanced translocation between chromosomes 9 and 22, t(9;22) (q34.1;q11.21). The BCR/ABL gene fusion is the genetic signature of the hematologic malignancy chronic myeloid leukemia (CML). It is also present in a smaller subset of predominantly adult onset B cell-acute lymphoblastic leukemia (B-ALL), where it confers a poor prognosis when treated with standard chemotherapy. Expression of the BCR/ABL fusion protein results in constitutively activated tyrosine phosphorylation of many cellular proteins with subsequent activation of a large number of cell signaling pathways, ultimately leading to neoplastic transformation. CML has been successfully treated with tyrosine kinase inhibitors such as imatinib, although increasing problems with acquired resistance to the inhibitor has led to alternate related drug therapies. Recently, studies have shown high rates of complete remission with the addition of imatinib to treatment protocols for Ph-positive B-ALL.
| Original language | English (US) |
|---|---|
| Title of host publication | Brenner's Encyclopedia of Genetics |
| Subtitle of host publication | Second Edition |
| Publisher | Elsevier Inc. |
| Pages | 313-315 |
| Number of pages | 3 |
| ISBN (Electronic) | 9780080961569 |
| ISBN (Print) | 9780123749840 |
| DOIs | |
| State | Published - Feb 27 2013 |
| Externally published | Yes |
Fingerprint
Keywords
- B-cell acute lymphoblastic leukemia
- Chronic myeloid leukemia
- Imatinib
- Inhibitors
- Myeloproliferative
- Philadelphia chromosome
- Tyrosine kinase
ASJC Scopus subject areas
- Agricultural and Biological Sciences(all)
- Biochemistry, Genetics and Molecular Biology(all)
- Medicine(all)
Cite this
BCR/ABL Oncogene. / Madden Felicella, M.; Jen, Kuang-Yu.
Brenner's Encyclopedia of Genetics: Second Edition. Elsevier Inc., 2013. p. 313-315.Research output: Chapter in Book/Report/Conference proceeding › Chapter
}
TY - CHAP
T1 - BCR/ABL Oncogene
AU - Madden Felicella, M.
AU - Jen, Kuang-Yu
PY - 2013/2/27
Y1 - 2013/2/27
N2 - The BCR/ABL oncogene is the product of the Philadelphia (Ph) chromosome, the derivative (22q) product of a balanced translocation between chromosomes 9 and 22, t(9;22) (q34.1;q11.21). The BCR/ABL gene fusion is the genetic signature of the hematologic malignancy chronic myeloid leukemia (CML). It is also present in a smaller subset of predominantly adult onset B cell-acute lymphoblastic leukemia (B-ALL), where it confers a poor prognosis when treated with standard chemotherapy. Expression of the BCR/ABL fusion protein results in constitutively activated tyrosine phosphorylation of many cellular proteins with subsequent activation of a large number of cell signaling pathways, ultimately leading to neoplastic transformation. CML has been successfully treated with tyrosine kinase inhibitors such as imatinib, although increasing problems with acquired resistance to the inhibitor has led to alternate related drug therapies. Recently, studies have shown high rates of complete remission with the addition of imatinib to treatment protocols for Ph-positive B-ALL.
AB - The BCR/ABL oncogene is the product of the Philadelphia (Ph) chromosome, the derivative (22q) product of a balanced translocation between chromosomes 9 and 22, t(9;22) (q34.1;q11.21). The BCR/ABL gene fusion is the genetic signature of the hematologic malignancy chronic myeloid leukemia (CML). It is also present in a smaller subset of predominantly adult onset B cell-acute lymphoblastic leukemia (B-ALL), where it confers a poor prognosis when treated with standard chemotherapy. Expression of the BCR/ABL fusion protein results in constitutively activated tyrosine phosphorylation of many cellular proteins with subsequent activation of a large number of cell signaling pathways, ultimately leading to neoplastic transformation. CML has been successfully treated with tyrosine kinase inhibitors such as imatinib, although increasing problems with acquired resistance to the inhibitor has led to alternate related drug therapies. Recently, studies have shown high rates of complete remission with the addition of imatinib to treatment protocols for Ph-positive B-ALL.
KW - B-cell acute lymphoblastic leukemia
KW - Chronic myeloid leukemia
KW - Imatinib
KW - Inhibitors
KW - Myeloproliferative
KW - Philadelphia chromosome
KW - Tyrosine kinase
UR - http://www.scopus.com/inward/record.url?scp=85043257709&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85043257709&partnerID=8YFLogxK
U2 - 10.1016/B978-0-12-374984-0.00144-3
DO - 10.1016/B978-0-12-374984-0.00144-3
M3 - Chapter
AN - SCOPUS:85043257709
SN - 9780123749840
SP - 313
EP - 315
BT - Brenner's Encyclopedia of Genetics
PB - Elsevier Inc.
ER -